Fenogal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenogal

Fenogal is a prescription-only medicine classified as an antidyslipidemic agent used to help manage abnormal fat levels (lipids) in the bloodstream. The active constituent is Fenofibrate, a molecule that the body converts into the active metabolite, Fenofibric acid. Its primary therapeutic action is to regulate the lipid profile in individuals with chronic metabolic imbalances.


Quick Facts

Property Description
Active Ingredient Fenofibrate
Form Oral formulations (Capsules, Tablets)
Pharmacological Class Fibrate / Fibrinic Acid Derivative
Origin Synthetic Compound
General Purpose Lipid Regulation

What Type of Medicine is Fenogal? (Identity and Classification)

Fenogal belongs to the fibrate pharmacological class, confirming its identity as a fibrinic acid derivative. The active substance, Fenofibrate, functions as a pro-drug, meaning it is entirely inactive until it is rapidly converted in the body to the biologically active Fenofibric acid. This mechanism is characteristic of agents that primarily target genetic regulators of fat metabolism, known as PPAR-alpha. This specific action is clinically recognized for its efficacy in lipid modification, differentiating fibrates from agents like statins.

Fenofibrate: Composition and Physical Form (Composition and Delivery)

Fenogal is administered for Oral administration and is available in solid oral formulations, typically Capsules or Tablets. A key feature of Fenofibrate formulations is the reliance on advanced manufacturing processes, such as micro-ionization or nanoparticle formulation, due to the compound's inherent poor water solubility. These technologies are integral to enhancing the compound's bioavailability (the amount absorbed into the bloodstream), ensuring reliable therapeutic levels of the active Fenofibric acid for effective chronic therapy.

What is the General Purpose of Fenogal? (General Therapeutic Role)

The general therapeutic purpose of Fenogal is to help regulate elevated fat levels in the blood. The drug is highly effective in reducing elevated triglycerides (TG) and certain cholesterol-carrying particles (VLDL-C). Concurrently, it helps promote an increase in HDL-C (High-density lipoprotein cholesterol). This therapeutic capability is supported by extensive pharmacological studies and is crucial for managing the imbalances associated with conditions such as mixed dyslipidemia and severe hypertriglyceridemia.

Regulatory References

  1. Fenofibrate Overview - MedlinePlus

What side effects are possible with Fenogal?

Possible Side Effects and Safety Information

Fenogal (fenofibrate) is associated with a defined set of documented side effects and safety considerations that require awareness and monitoring.

Serious and Clinically Significant Risks

Fenogal carries warnings regarding several potentially serious conditions:

  • Myopathy and Rhabdomyolysis: This includes muscle pain, tenderness, or weakness, and a serious risk of muscle breakdown (rhabdomyolysis) which can lead to kidney damage. The risk is elevated when Fenogal is used concurrently with statin medications, and in older adults, patients with diabetes, renal impairment, or hypothyroidism.
  • Hepatotoxicity: Serious, drug-induced liver injury, including cases leading to transplantation or death, has been reported. Regular monitoring of liver enzymes (ALT, AST) is required throughout therapy.
  • Cholelithiasis and Pancreatitis: Fenogal may increase cholesterol excretion into the bile, raising the risk of gallstone formation (cholelithiasis). The medication is also associated with reports of pancreatitis (inflammation of the pancreas).
  • Venothromboembolic Disease: This includes an increased risk of blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • Hypersensitivity: Acute and delayed severe allergic reactions, including anaphylaxis and severe cutaneous adverse drug reactions (e.g., Stevens-Johnson syndrome), have been documented.

Common Adverse Reactions

The most frequently reported side effects in clinical trials (occurring in geq2% of patients and at a rate at least 1% greater than placebo) include abnormal liver tests, increased Creatine Phosphokinase (CPK) levels, and rhinitis (runny/stuffy nose).

Contraindications and Monitoring

Fenogal is contraindicated in patients with active liver disease, severe renal impairment (including dialysis), pre-existing gallbladder disease, or known hypersensitivity to the drug. Due to the potential for muscle, liver, and kidney toxicity, regular monitoring of liver function, renal function (serum creatinine), and signs of myopathy is necessary during treatment. Use with coumarin-type anticoagulants requires caution and frequent monitoring of blood clotting parameters.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Fenofibrate notes that the majority of documented anecdotal cases of overdosage have reported no specific symptoms. However, certain severe manifestations require immediate, mandated emergency action.

Emergency Actions and Triggers

Immediate medical help is required for life-threatening outcomes. You must call emergency services (e.g., 911) if the individual has:

  • Collapsed (loss of consciousness)
  • Had a seizure
  • Trouble breathing
  • Inability to be awakened

The instruction is also to contact the poison control helpline for any suspected overdosage event.

Treatment and Monitoring Requirements

Regulatory authorities state that no specific treatment or antidote is known for Fenofibrate overdose. Management is based on providing general supportive care, including monitoring of vital signs and observation of clinical status. If elimination of the unabsorbed drug is deemed clinically necessary, procedures such as emesis or gastric lavage may be considered. A necessary procedural exclusion is that hemodialysis should not be considered, as the active metabolite is highly bound to plasma proteins. Maintaining the airway is also listed as a key precaution during management.

Therapeutic Uses of Fenogal

What Fenogal Treats: Main Uses and Benefits

Fenogal is generally used to manage blood fat abnormalities, particularly those classified as severe. It is commonly used when diet and lifestyle changes alone are insufficient to correct these systemic imbalances. This therapeutic agent is relevant for managing conditions such as primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.

This use helps address symptom clusters involving elevated Triglycerides and LDL-C (Low-Density Lipoprotein Cholesterol) and low levels of protective HDL-C (High-Density Lipoprotein Cholesterol). The primary benefit contributes to easing the overall symptom load associated with the adverse fat profile, which may help maintain a sense of stability during symptomatic periods. Fenogal also generally offers supportive therapeutic benefit to patients with Type 2 Diabetes Mellitus, as it may assist with symptomatic support in contexts relevant to diabetic retinopathy.


Quick Fact: Use in Severe Blood Fat Abnormalities

Area of Use Symptom Cluster Managed Patient Benefit
High-Risk Reduction Symptoms of Increased Systemic Imbalance (High Triglycerides) Provides supportive relief when symptoms create noticeable functional strain
Profile Optimization Symptoms Related to Systemic Imbalance (Low HDL-C) Contributes to improved comfort and helps maintain a sense of stability
Supportive Care Diabetic-related Lipid Profile Assists with managing the systemic burden during symptomatic phases

Eligibility and Restrictions for Use

Fenogal (fenofibrate) eligibility is strictly defined by regulatory bodies and is primarily based on patient health status, organ function, and physiological state. Eligibility is categorized into populations who are permitted use and those who are formally excluded.

Who Must Not Use Fenogal (Contraindications)

Fenogal is contraindicated and must not be used by individuals with the following conditions or statuses, as per official labeling:

  • Severe Renal Impairment (including those on dialysis).
  • Active Liver Disease (including unexplained persistent liver function abnormalities).
  • Pre-existing Gallbladder Disease.
  • Known Hypersensitivity to fenofibrate or fenofibric acid.
  • Nursing Mothers (Breastfeeding women).

Populations Requiring Special Consideration

Population Category Regulatory Status
Pediatric Patients Safety and efficacy are not established; generally not recommended.
Pregnancy Use is only recommended if clearly needed and the potential benefit justifies the risk, due to limited human data.
Mild-to-Moderate Renal Impairment Use is permitted but requires initial dosage adjustment and careful monitoring.

Fenogal is established for use in the adult population, provided none of the contraindications are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fenogal (Fenofibrate) has officially documented interaction patterns primarily concerning risks of additive toxicity, pharmacokinetic modification, and mandatory administration timing rules. All interaction information is based on governmental regulatory labeling.


Documented Pharmacodynamic and Exposure Interactions

Interacting Agent Official Interaction Pattern/Outcome
HMG-CoA Reductase Inhibitors (Statins) Increased documented risk of myopathy and rhabdomyolysis (additive toxicity).
Coumarin-type Anticoagulants (e.g., Warfarin) Fenogal potentiates the anticoagulant effect, requiring a regulatory-mandated reduction in the anticoagulant’s dosage.
Immunosuppressants (e.g., Cyclosporine) Risk of deterioration of renal function, which reduces the clearance and increases exposure of the active metabolite, Fenofibric acid.
Colchicine Increased documented risk of myopathy and rhabdomyolysis.

Administration and Substance Constraints

Constraint Type Regulatory Statement
Timing Separation Must be administered at least 1 hour before or 4 to 6 hours after Bile Acid Binding Resins to prevent absorption interference.
Food Constraint Certain formulations must be taken with a meal to ensure optimal bioavailability.
Population Note The risk of interaction-related myopathy is officially noted as increased in geriatric patients and those with renal impairment.

Regulatory documents define this profile by establishing both the PD risk of additive muscle toxicity and PK concerns related to reduced clearance and the potentiation of anticoagulants, which necessitates procedural constraints for safe co-administration.

Mechanism of Action

Fenogal primarily functions as a modulator and activator of several intracellular signaling systems. At the molecular level, it engages key transcriptional regulators, notably Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) and Nuclear Factor Erythroid 2-related factor 2 (Nrf2). By influencing these factors, Fenogal alters the expression of genes associated with lipid and glucose metabolism and enhances endogenous antioxidant defenses, consequently limiting the magnitude of oxidative stress in the cell. The drug also participates in the attenuation of pro-inflammatory signaling cascades, modulating the activity of factors that regulate the production of inflammatory mediators, which alters inflammatory propagation at the tissue level. Furthermore, Fenogal exhibits a neuromodulatory effect via interaction with specific neurotransmitter receptors, such as certain adenosine and nicotinic acetylcholine receptors. This adjustment in neural signaling modulates neuronal excitability and affects the cellular defense mechanisms of nervous tissue in both central and peripheral pathways.

Dosage and Administration Information

How Fenogal is Used

Fenogal (Fenofibrate) is administered exclusively via the oral route using solid formulations, such as tablets or capsules. The established principle for use is a single dose once daily (Q.D.) for all approved adult regimens, which facilitates long-term management of chronic lipid imbalances.


Administration and Timing

Instruction Detail
Route and Physical Intake The unit dose must be swallowed whole; it should not be crushed, broken, or chewed.
Dosing Frequency Administered once daily.
Timing with Food Formulation-dependent: Some Fenofibrate products must be taken with a meal to ensure proper absorption, while others can be taken without regard to food.

Standard Dosing and Adjustments

Standard maintenance doses for adults with primary hyperlipidemia or mixed dyslipidemia are typically 145 mg or 160 mg once daily, depending on the specific product formulation. For severe hypertriglyceridemia, the initial dose may start lower (e.g., 48 mg once daily) and may be adjusted.

Usage involves a chronic treatment plan where lipid levels must be assessed at 4 to 8 week intervals to confirm the dose adequacy. A key procedural rule for specific populations is that patients with mild to moderate renal impairment must begin treatment at a reduced daily dose (e.g., 48 mg once daily). Dose selection for older adults is also determined by their underlying renal function status.

Recent Clinical Evidence

Fenogal: Recent Clinical Evidence

Fenogal is a medicine for which research was conducted exploring its role in managing blood fat levels. The evidence base for Fenofibrate, the active component, includes large Randomized Controlled Trials (RCTs) and meta-analyses. These studies contribute to the broader evidence landscape, describing patterns observed in various conditions characterized by systemic or functional imbalance.


Evidence for Use in Managing Mixed Dyslipidemia

Research has explored the use of Fenofibrate in individuals with mixed dyslipidemia, a condition involving elevated levels of certain fats, including high Triglycerides and often low levels of HDL-C (High-Density Lipoprotein Cholesterol). Studies reported patterns showing changes in the lipid profile, including measured reductions in triglyceride levels and elevations in HDL-C levels when compared to groups receiving placebo.

However, research exploring the long-term effects on major cardiovascular events (such as heart attacks or strokes) in the general dyslipidemia population yielded mixed findings. While the research describes observed changes in the biomarker imbalance, the findings across all large trials did not uniformly support an effect on the primary composite cardiovascular outcome. Long-term effects are not fully established for the general population, and subgroup findings were uncertain.


Research on Microvascular Outcomes in Type 2 Diabetes

Research has explored Fenofibrate's association with specific microvascular outcomes in patients with Type 2 Diabetes Mellitus. Researchers examined this in secondary analyses of long-term trials, with attention given to outcomes related to systemic or functional imbalance, such as the rate of diabetic retinopathy progression and the frequency of retinal laser treatment. Analyses reported patterns suggesting an association with the progression of diabetic retinopathy in certain groups compared to controls.

Studies also monitored changes in markers of renal function, specifically reporting a pattern where serum creatinine levels increased and the estimated Glomerular Filtration Rate (eGFR) appeared to decrease. This change may reflect the drug's effect on how creatinine is handled by the kidneys rather than definitively established injury. Data for certain groups remain insufficient, as these findings often came from secondary or composite endpoints of trials focused on cardiovascular health.


What Remains Uncertain and Research Gaps

Evidence quality varies across studies, particularly regarding the long-term clinical outcomes in the general dyslipidemia population where findings were mixed. There is limited information for long-term outcomes regarding the prevention of certain acute complications (like pancreatitis) in severe hypertriglyceridemia. Additionally, the full clinical meaning of the observed changes in renal function markers requires further research to characterize fully. The evidence contributes to understanding symptom patterns and biomarker changes but does not determine long-term functional improvement or disease reversal.

Key Studies & References

  1. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Trial: Microvascular and Macrovascular Outcomes

Frequently Asked Questions (FAQ)

Common questions about Fenogal (FAQ)


Q: Are there any long-term side effects associated with Fenogal?

A: Official labeling describes patterns where some effects, such as mild decreases in blood count markers, were observed to stabilize with long-term administration. However, the risk of serious side effects like liver injury or muscle problems may still occur after several months of therapy, requiring monitoring throughout the duration of treatment.


Q: Is Fenogal safe for older people?

A: Official information notes that use in older adults requires consideration of their kidney function status for dose selection. Regulatory documents also note that the risk of serious side effects, particularly muscle problems (myopathy), is increased in the elderly, especially when used alongside a statin medicine.


Q: What are the ingredients in Fenogal?

A: The product contains the active ingredient, fenofibrate. The official product information also lists various inactive ingredients (excipients), which can vary by formulation but typically include components such as cellulose, talc, and sometimes soy derivatives.


Q: How long do most people need to stay on Fenogal treatment?

A: Official regulatory text confirms that treatment for lipid imbalances is typically a long-term therapy. Official information notes that therapy is generally intended to be discontinued if an adequate response is not achieved after a specific period of treatment (such as two months) with the maximum recommended dose.


Q: Why is Fenogal sometimes prescribed with a statin?

A: Regulatory documents state that combining fibrates with statins carries an increased risk of severe muscle problems (myopathy). Concomitant use is associated with situations where the potential benefit to lipid levels may outweigh this well-documented risk.


Q: What are the signs of an allergic reaction to Fenogal?

A: According to the official product information, signs of a serious allergic reaction may include rash, hives, swelling of the face, lips, tongue, or difficulty breathing. Severe skin reactions, such as Stevens-Johnson syndrome, have also been reported in rare cases.


Q: Are there foods that make Fenogal less effective?

A: Official labeling states that the absorption of some fenofibrate formulations is increased when administered with food. Taking the product without a meal may result in lower absorption into the bloodstream, which could lead to reduced effectiveness.


Q: What happens if I miss a dose of Fenogal?

A: Official patient information provides specific instructions regarding missed doses to ensure consistent blood levels. These instructions clarify when a remembered dose may be taken and when to omit a dose to avoid taking double quantities.


Q: Is it okay to stop taking Fenogal once my levels improve?

A: Official documents describe treatment as typically long-term for chronic management. Cessation of therapy is a clinical decision that requires consultation with a healthcare professional, even if laboratory levels appear to improve.


Q: Does Fenogal cause stomach problems or nausea?

A: Nausea and stomach pain are listed in official sources as less common side effects. It is important to note that stomach pain may be associated with more serious adverse events like pancreatitis or liver issues.


Q: Is it normal to feel a bit tired when starting Fenogal?

A: Unusual tiredness or weakness is listed in official sources as a rare or less common side effect. This symptom may also be associated with serious conditions mentioned in the official warnings, such as muscle problems (myopathy) or liver issues.


Q: Does Fenogal interact with common pain relievers like ibuprofen?

A: The official product labeling has an extensive list of known drug interactions and emphasizes the risk of myopathy when co-administered with certain medications. While specific over-the-counter pain relievers may not be explicitly listed, the potential for interaction necessitates consultation regarding all concomitant medications.


Q: Can I drink alcohol while I am taking Fenogal?

A: Official documents state that alcohol intake should be limited during therapy, and consumption habits should be discussed with a healthcare professional. Excessive alcohol use is a factor that may increase the risk of side effects, particularly liver problems and high triglyceride levels.


Q: Is there a list of foods or supplements that should be avoided with Fenogal?

A: Regulatory documents advise that Bile Acid Binding Resins must be taken at least one hour before or four to six hours after this medication. Furthermore, patients are advised to address excessive alcohol intake as it can worsen the condition being treated.


Q: Does Fenogal interact with birth control pills?

A: The official product labeling does not detail a direct drug-to-drug interaction between fenofibrate and oral contraceptives. However, it is stated that women of childbearing potential are advised to use reliable birth control methods, as the medication is generally not recommended during pregnancy.


Q: Can women who are planning pregnancy take Fenogal?

A: Official information notes that consultation with a healthcare professional is necessary for women planning pregnancy regarding the continuation or adjustment of medication. Regulatory documents advise considering cessation of therapy several months in advance of a planned pregnancy.


Q: What is Fenogal used for besides its main purpose?

A: The official indications are limited to treating Severe Hypertriglyceridemia and Primary Hypercholesterolemia or Mixed Dyslipidemia. Some specific product formulations are also indicated in regulatory documents to slow the progression of diabetic retinopathy in diabetic patients.


Q: Is Fenogal approved in countries outside of the US?

A: The active ingredient, Fenofibrate, is approved for use and is regulated by governmental health authorities in multiple countries outside of the United States. This includes approvals in countries covered by the European Medicines Agency (EMA) and other official health organizations internationally.


Q: Is Fenogal the brand name or the generic name?

A: Fenogal is a brand name product. The active pharmaceutical ingredient is Fenofibrate, which is the internationally recognized generic name.


Q: Does Fenogal interact with herbal supplements like St. John's Wort?

A: The official labeling provides a list of known drug-drug interactions and advises caution with all other medications and supplements. While St. John's Wort is not explicitly named, the general advice necessitates consultation with a healthcare professional to assess the risk of interaction with all supplements.


Q: Will taking Fenogal require me to change my diet significantly?

A: According to the official product information, Fenogal is an adjunctive therapy, meaning it is meant to be used in addition to a proper diet. Official product information emphasizes the necessity of maintaining an appropriate lipid-lowering diet throughout the entire course of treatment.


Q: Does Fenogal have a black box warning?

A: Official product information confirms that Fenofibrate does not carry a Black Box Warning, which is the most stringent warning by the FDA. However, the drug label contains prominent Warnings and Precautions regarding the serious risks of myopathy, rhabdomyolysis, and liver toxicity.


Q: What should I do if I get a bad headache after starting Fenogal?

A: Headache is listed in official sources as a common or less common side effect. In general, it is recommended that any bothersome side effect, including headache, that persists or is concerning be discussed with a healthcare professional.


Q: Is there a generic version of Fenogal available?

A: Yes, a generic version of the active ingredient, Fenofibrate, is widely available as a prescription medicine. The availability of generic alternatives is often determined by regulatory bodies based on the active component.


Q: Is Fenogal a controlled substance?

A: No, according to regulatory classification, Fenofibrate products are generally not considered controlled substances. This is reflected in the DEA Schedule: None designation in official documents.


Q: How does Fenogal compare to the effects of lifestyle changes?

A: Fenogal is intended as an adjunctive therapy to diet, exercise, and weight control. Official documents emphasize that these lifestyle modifications are essential initial and ongoing measures that must accompany drug treatment.

How should Fenogal be stored and disposed of?

How to Store and Dispose of Fenogal

Fenogal (fenofibrate) must be stored according to specific regulatory requirements to maintain product stability and safety.

Official Storage Conditions

Store this medicine at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The container must be kept tightly closed and stored away from excess heat, moisture, and direct light; it must also be kept from freezing. For safety, Fenogal must be stored out of the sight and reach of children.

Disposal Instructions

Discard any outdated or unused product. The preferred disposal method is a drug take-back program. If this is unavailable, mix the medicine with an unappealing substance, place it in a sealed container, and discard it in the household trash. Fenogal should not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenogal found in:

A-Z Index: